TEVA Teva Pharmaceutical Industries Ltd

  1. Stocks
  2. Healthcare
  3. NYSE: TEVA

Price (delayed)

$10.01

Market cap

$11.22B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2

Enterprise value

$29.56B

Highlights
The debt has declined by 6% year-on-year
TEVA's net income has dropped by 112% year-on-year and by 39% since the previous quarter
Teva Pharmaceutical Industries's EPS has shrunk by 111% YoY and by 39% QoQ
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Website: http://www.tevapharm.com
Peers: PFE MRK

Key stats

What are the main financial stats of TEVA
Market
Shares outstanding
1.12B
Market cap
$11.22B
Enterprise value
$29.56B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.59
Price to sales (P/S)
0.75
EV/EBIT
N/A
EV/EBITDA
118.73
EV/Sales
1.97
Earnings
Revenue
$15.02B
EBIT
-$982M
EBITDA
$249M
Free cash flow
$1.17B
Per share
EPS
-$2
Free cash flow per share
$1.05
Book value per share
$6.29
Revenue per share
$13.41
TBVPS
$18.07
Balance sheet
Total assets
$43.1B
Total liabilities
$35.39B
Debt
$21.02B
Equity
$7.05B
Working capital
$245M
Liquidity
Debt to equity
2.98
Current ratio
1.02
Quick ratio
0.52
Net debt/EBITDA
73.68
Margins
EBITDA margin
1.7%
Gross margin
45.4%
Net margin
-14.9%
Operating margin
-7.6%
Efficiency
Return on assets
-5.1%
Return on equity
-28.3%
Return on invested capital
-3.6%
Return on capital employed
-3.1%
Return on sales
-6.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

TEVA stock price

How has the Teva Pharmaceutical Industries stock price performed over time
Intraday
-2.05%
1 week
-6.45%
1 month
3.2%
1 year
29.33%
YTD
9.76%
QTD
32.93%

Financial performance

How have Teva Pharmaceutical Industries's revenue and profit performed over time
Revenue
$15.02B
Gross profit
$6.82B
Operating income
-$1.14B
Net income
-$2.23B
Gross margin
45.4%
Net margin
-14.9%
The net margin has dropped by 119% year-on-year and by 39% since the previous quarter
TEVA's net income has dropped by 112% year-on-year and by 39% since the previous quarter
The operating margin rose by 22% QoQ but it fell by 7% YoY
TEVA's operating income is up by 21% from the previous quarter but it is down by 3.3% YoY

Growth

What is Teva Pharmaceutical Industries's growth rate over time

Valuation

What is Teva Pharmaceutical Industries stock price valuation
P/E
N/A
P/B
1.59
P/S
0.75
EV/EBIT
N/A
EV/EBITDA
118.73
EV/Sales
1.97
Teva Pharmaceutical Industries's EPS has shrunk by 111% YoY and by 39% QoQ
TEVA's price to book (P/B) is 62% higher than its 5-year quarterly average of 1.0 and 35% higher than its last 4 quarters average of 1.2
Teva Pharmaceutical Industries's equity has decreased by 22% YoY and by 10% QoQ
The P/S is 27% above the last 4 quarters average of 0.6 and 9% above the 5-year quarterly average of 0.7
TEVA's revenue is down by 2.7% year-on-year

Efficiency

How efficient is Teva Pharmaceutical Industries business performance
TEVA's ROE has plunged by 162% YoY and by 48% from the previous quarter
Teva Pharmaceutical Industries's return on assets has shrunk by 132% YoY and by 42% QoQ
Teva Pharmaceutical Industries's return on sales has increased by 25% QoQ but it has decreased by 7% YoY
The company's return on invested capital rose by 22% QoQ but it fell by 16% YoY

Dividends

What is TEVA's dividend history
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
Recent dividends

Financial health

How did Teva Pharmaceutical Industries financials performed over time
The total assets is 22% greater than the total liabilities
TEVA's quick ratio is down by 12% YoY and by 3.7% from the previous quarter
Teva Pharmaceutical Industries's current ratio has decreased by 8% YoY and by 7% QoQ
The debt is 198% greater than the equity
Teva Pharmaceutical Industries's equity has decreased by 22% YoY and by 10% QoQ
TEVA's debt to equity is up by 20% YoY and by 11% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.